ARK Investment Management LLC Has $265.88 Million Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

ARK Investment Management LLC raised its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 6.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,213,257 shares of the company's stock after buying an additional 427,274 shares during the period. Twist Bioscience makes up approximately 1.6% of ARK Investment Management LLC's portfolio, making the stock its 19th largest position. ARK Investment Management LLC owned 12.48% of Twist Bioscience worth $265,881,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Charles Schwab Investment Management Inc. increased its stake in shares of Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company's stock worth $8,965,000 after buying an additional 14,511 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Twist Bioscience by 559.5% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company's stock worth $2,159,000 after acquiring an additional 90,413 shares in the last quarter. Dark Forest Capital Management LP lifted its stake in Twist Bioscience by 121.3% during the third quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company's stock worth $597,000 after purchasing an additional 16,142 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Twist Bioscience in the third quarter valued at approximately $451,000. Finally, Invesco Ltd. boosted its holdings in shares of Twist Bioscience by 1,496.2% in the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company's stock valued at $16,836,000 after buying an additional 778,944 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TWST shares. The Goldman Sachs Group raised Twist Bioscience from a "neutral" rating to a "buy" rating and increased their price objective for the company from $25.00 to $45.00 in a report on Wednesday, January 17th. Barclays raised their price objective on shares of Twist Bioscience from $30.00 to $45.00 and gave the stock an "overweight" rating in a research report on Thursday, January 25th. Finally, Scotiabank upped their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a report on Monday, February 5th.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $0.17 during mid-day trading on Thursday, reaching $34.31. The stock had a trading volume of 1,187,678 shares, compared to its average volume of 949,821. The business has a 50 day simple moving average of $36.47 and a 200 day simple moving average of $28.81. Twist Bioscience Co. has a twelve month low of $11.46 and a twelve month high of $43.21. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -9.50 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. During the same quarter last year, the firm posted ($0.74) EPS. The business's revenue was up 31.8% compared to the same quarter last year. As a group, sell-side analysts expect that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Buying and Selling

In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the business's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the sale, the director now directly owns 64,169 shares in the company, valued at $2,244,631.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of Twist Bioscience stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares in the company, valued at $2,244,631.62. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,487 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $55,658.41. Following the transaction, the chief executive officer now directly owns 516,409 shares of the company's stock, valued at $19,329,188.87. The disclosure for this sale can be found here. Insiders have sold a total of 8,301 shares of company stock worth $294,282 in the last quarter. Company insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.